Top 25 Antibiotic Drugs Manufacturers 2018
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 250-page report you will receive 181 tables and 111 figures– all unavailable elsewhere.
The 250-page report provides clear detailed insight into the top 25 antibiotic drugs manufacturers. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
- Global Antibiotic Drugs Market Forecast from 2018-2028, further segmented by type:
- Cephalosporins
- Penicillins
- Fluoroquinolones
- Macrolides
- Carbapenems
- Others
- This report provides analysis of the leading antibiotic drugs manufacturers in the US, including forecasts from 2018-2028 of the company’s antibiotic drugs revenues, where possible:
- Pfizer: Sulperazon, Unasyn, Zithromax, Dalacin, Merrem/Meropen, Zyvox, Tygacil, Others
- Merck & Co.: Cubicin, Invanz, Avelox, Primaxin, Others
- Johnson & Johnson: Zeftera, Sirturo, Others
- Cubist Pharmaceuticals: Cubicin, Sivextro Oral
- Abbott Laboratories: Baxin, Others
- Eli Lilly & Co.: Vancocin, Ceclor
- Melinta Therapeutics, Inc: Orbactiv, Others
- This report provides analysis of the leading antibiotic drugs manufacturers in Europe, including forecasts from 2018-2028 of the company’s antibiotic drugs revenues, where possible:
- Novartis: Vigamox, Ciprodex, TOBI Podhaler, Cubicin
- GlaxoSmithKline: Ceftin/Zinnat, Augmentin IR, Amoxil, Others
- Bayer: Avelox, Cipro/Cirpobay
- Allergan: Zinforo/Teflaro, Dalbavancin, Others
- Roche: Rocephin
- Sanofi: Targocid, Others
- STADA Arzneimittel: Amoxicillin, Diclofenac Sodium
- This report provides analysis of the leading antibiotic drugs manufacturers in Japan, including forecasts from 2018-2028 of the company’s antibiotic drugs revenues, where possible:
- Shionogi & Co., Ltd.: Flomox/Flumarin, Others
- Taisho Pharmaceutical Holdings: Geninax, Biaxin/Clarith, Zosyn/Tazocin
- Daiichi Sankyo: Cravit, Levaquin, Others
- Meiji Holdings Company, Ltd.: Meiact/Spectracef, Others
- Astellas Pharma: Dificid, Others
- This report provides analysis of the leading antibiotic drugs manufacturers in other countries, including forecasts from 2018-2028 of the company’s antibiotic drugs revenue, where possible:
- Sun Pharmaceutical Industries: Ciprofloxacin Hydrochloride, Others
- Cipla: Amoxicillin, Others
- Lupin: Cefixime, Cephalexin, Others
- Shanghai Pharmaceuticals Holding: Cefotaxime Sodium, Cefotiam Hydrochloride, Ceftriaxone Sodium
- Dr. Reddy’s Laboratories: Cefotaxime Sodium, Cefotiam Hydrochloride, Ceftriaxone Sodium
- TaiGen Biotechnology: Taigexyn
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
- 1. Report Overview
- 1.1 Global Antibiotics Drugs Manufacturer Market Overview
- 1.2 Overview of Findings
- 1.3 Structure of the Report
- 1.4 Global Antibiotics Drugs Manufacturer Market Segmentation
- 1.5 Why You Should Read This Report
- 1.6 Key Questions Answered by This Analytical Report
- 1.7 Who is This Report For?
- 1.8 Methodology
- 1.9 Associated Visiongain Report
- 1.10 About Visiongain
- 2. Introduction to Antibiotics Drugs Manufacturer
- 2.1 An Introduction to Antibiotics Drugs Manufacturer
- 2.1.1. Cephalosporins
- 2.1.2. Penicillins
- 2.1.3. Quinolones/Fluoroquinolones
- 2.1.4. Macrolides
- 2.1.5. Carbapenems
- 2.2. Antibiotics Drugs Manufacturer Market: Drivers, Restrains and Opportunities
- 2.2.1. Drivers
- 2.2.1.1. Need of new broad-spectrum agents
- 2.2.1.2. Increase in Government Funding
- 2.2.1.3. Infection control in health care settings
- 2.2.1.4. Rapidly growing antibacterial resistance
- 2.2.2. Restrains
- 2.2.2.1. Inappropriate prescription and patient compliance
- 2.2.2.2. Lack of return on investment
- 2.2.3. Opportunities
- 2.2.3.1. Public-Private Funding
- 3. Antibiotics Drugs: World Market 2018-2028
- 3.1 Global Antibiotics Drugs Market Forecast, 2018-2028
- 3.2 Global Antibiotics Drugs Market, by Automation Type: Sales Forecast 2018-2028
- 3.3 Leading Antibiotics Drugs Manufacturer
- 3.4 Leading Companies in the Antibiotics Drugs Market
- 3.5 Antibiotics Drugs Market Segments: Sales Forecasts 2018-2028
- 3.5.1 Cephalosporins Drugs Market: Sales Forecast 2018-2028
- 3.5.2 Penicillins Drugs Market: Sales Forecast 2018-2028
- 3.5.3 Fluoroquinolones Drugs Market: Sales Forecast 2018-2028
- 3.5.4 Macrolides Drugs Market: Sales Forecast 2018-2028
- 3.5.5 Carbapenems Drugs Market: Sales Forecast 2018-2028
- 3.5.6 Others Drugs Market: Sales Forecast 2018-2028
- 4. Leading US Antibiotics Drugs Manufacturers 2018-2028
- 4.1 Pfizer, Inc.: Overview
- 4.1.1 Pfizer: Antibiotics Drugs Portfolio
- 4.1.2 Pfizer Antibiotics Drug Sales Forecast 2018-2028
- 4.1.2.1 Sulperazon
- 4.1.2.2 Sulperazon: Sales Forecast 2018-2028
- 4.1.2.3 Unasyn
- 4.1.2.4 Unasyn: Sales Forecast 2018-2028
- 4.1.2.5 Zithromax
- 4.1.2.6 Zithromax: Sales Forecast 2018-2028
- 4.1.2.7 Dalacin
- 4.1.2.8 Dalacin: Sales Forecast 2018-2028
- 4.1.2.9 Merrem/Meropen
- 4.1.2.10 Merrem/Meropen: Sales Forecast 2018-2028
- 4.1.2.11 Zyvox
- 4.1.2.12 Zyvox: Sales Forecast 2018-2028
- 4.1.2.13 Tygacil
- 4.1.2.14 Tygacil: Sales Forecast 2018-2028
- 4.1.2.15 Others
- 4.1.2.16 Others: Sales Forecast 2018-2028
- 4.1.3 Pfizer: SWOT Analysis
- 4.2 Merck & Co.: Overview
- 4.2.1 Merck & Co.: Antibiotics Drugs Portfolio
- 4.2.2 Merck & Co. Antibiotics Drug Sales Forecast 2018-2028
- 4.2.2.1 Cubicin
- 4.2.2.2 Cubicin: Sales Forecast 2018-2028
- 4.2.2.3 Invanz
- 4.2.2.4 Invanz: Sales Forecast 2018-2028
- 4.2.2.5 Avelox
- 4.2.2.6 Avelox: Sales Forecast 2018-2028
- 4.2.2.7 Primaxin
- 4.2.2.8 Primaxin: Sales Forecast 2018-2028
- 4.2.2.9 Others
- 4.2.2.10 Others: Sales Forecast 2018-2028
- 4.2.3. Merck & Co.: SWOT Analysis
- 4.3 Johnson & Johnson: Overview
- 4.3.1 Johnson & Johnson: Antibiotics Drugs Portfolio
- 4.3.2 Johnson & Johnson Antibiotics Drug Sales Forecast 2018-2028
- 4.3.2.1 Zeftera
- 4.3.2.2 Zeftera: Sales Forecast 2018-2028
- 4.3.2.3 Sirturo
- 4.3.2.4 Sirturo: Sales Forecast 2018-2028
- 4.3.2.5 Others
- 4.3.2.6 Others: Sales Forecast 2018-2028
- 4.3.3. Johnson & Johnson: SWOT Analysis
- 4.4 Cubist Pharmaceuticals: Overview
- 4.4.1 Cubist Pharmaceuticals: Antibiotics Drugs Portfolio
- 4.4.2 Cubist Pharmaceuticals Antibiotics Drug Sales Forecast 2018-2028
- 4.4.2.1 Cubicin
- 4.4.2.2 Cubicin: Sales Forecast 2018-2028
- 4.4.2.3 Sivextro Oral (Tedizolid)
- 4.4.2.4 Sivextro Oral: Sales Forecast 2018-2028
- 4.4.2.5 Others
- 4.4.2.6 Others: Sales Forecast 2018-2028
- 4.4.3. Cubist Pharmaceuticals.: SWOT Analysis
- 4.5 Abbott Laboratories: Overview
- 4.5.1. Abbott Laboratories: Antibiotics Drugs Portfolio
- 4.5.2 Abbott Laboratories Antibiotics Drug Sales Forecast 2018-2028
- 4.5.2.1 Baxin
- 4.5.2.2 Baxin: Sales Forecast 2018-2028
- 4.5.2.3 Others
- 4.5.2.4 Others: Sales Forecast 2018-2028
- 4.5.3. Abbott Laboratories.: SWOT Analysis
- 4.6 Eli Lilly & Co.: Overview
- 4.6.1. Eli Lilly & Co.: Antibiotics Drugs Portfolio
- 4.6.2 Eli Lilly & Co. Antibiotics Drug Sales Forecast 2018-2028
- 4.6.2.1 Vancocin
- 4.6.2.2 Vancocin: Sales Forecast 2018-2028
- 4.6.2.3 Ceclor
- 4.6.2.4 Ceclor: Sales Forecast 2018-2028
- 4.6.3. Eli Lilly & Co.: SWOT Analysis
- 4.7 Melinta Therapeutics, Inc.: Overview
- 4.7.1 Melinta Therapeutics, Inc.: Antibiotics Drugs Portfolio
- 4.7.2 Melinta Therapeutics, Inc. Antibiotics Drug Sales Forecast 2018-2028
- 4.7.2.1 Orbactiv
- 4.7.2.2 Orbactiv: Sales Forecast 2018-2028
- 4.7.2.3 Others
- 4.7.2.4 Others: Sales Forecast 2018-2028
- 4.7.3. Melinta Therapeutics, Inc: SWOT Analysis
- 5. Leading Europe Antibiotics Drugs Manufacturers 2018-2028
- 5.1 Novartis: Overview
- 5.1.1 Novartis: Antibiotics Drugs Portfolio
- 5.1.2 Novartis Antibiotics Drug Sales Forecast 2018-2028
- 5.1.2.1 Vigamox
- 5.1.2.2 Vigamox: Sales Forecast 2018-2028
- 5.1.2.3 Ciprodex
- 5.1.2.4 Ciprodex: Sales Forecast 2018-2028
- 5.1.2.5 TOBI Podhaler
- 5.1.2.6 TOBI Podhaler: Sales Forecast 2018-2028
- 5.1.2.7 Cubicin
- 5.1.2.8 Cubicin: Sales Forecast 2018-2028
- 5.1.3 Novartis: SWOT Analysis
- 5.2 GlaxoSmithKline plc: Overview
- 5.2.1 GlaxoSmithKline plc: Antibiotics Drugs Portfolio
- 5.2.2 GlaxoSmithKline plc Antibiotics Drug Sales Forecast 2018-2028
- 5.2.2.1 Ceftin/Zinnat
- 5.2.2.2 Ceftin/Zinnat: Sales Forecast 2018-2028
- 5.2.2.3 Augmentin IR
- 5.2.2.4 Augmentin IR: Sales Forecast 2018-2028
- 5.2.2.5 Amoxil (Amoxicillin)
- 5.2.2.6 Amoxil: Sales Forecast 2018-2028
- 5.2.2.7 Others
- 5.2.2.8 Others: Sales Forecast 2018-2028
- 5.2.3 GlaxoSmithKline plc: SWOT Analysis
- 5.3 Bayer AG: Overview
- 5.3.1 Bayer AG: Antibiotics Drugs Portfolio
- 5.3.2 Bayer AG Antibiotics Drug Sales Forecast 2018-2028
- 5.3.2.1 Avelox
- 5.3.2.2 Avelox: Sales Forecast 2018-2028
- 5.3.2.3 Cipro/Cirpobay
- 5.3.2.4 Cipro/Cirpobay: Sales Forecast 2018-2028
- 5.3.3 Bayer AG: SWOT Analysis
- 5.4 Allergan plc: Overview
- 5.4.1 Allergan plc: Antibiotics Drugs Portfolio
- 5.4.2 Allergan plc Antibiotics Drug Sales Forecast 2018-2028
- 5.4.2.1 Zinforo/Teflaro
- 5.4.2.2 Zinforo/Teflaro: Sales Forecast 2018-2028
- 5.4.2.3 Dalbavancin
- 5.4.2.4 Dalbavancin: Sales Forecast 2018-2028
- 5.4.2.5 Others
- 5.4.2.6 Others: Sales Forecast 2018-2028
- 5.4.3. Allergan plc: SWOT Analysis
- 5.5. F. Hoffmann-La Roche AG: Overview
- 5.5.1 F. Hoffmann-La Roche AG: Antibiotics Drugs Portfolio
- 5.5.2. F. Hoffmann-La Roche AG Antibiotics Drug Sales Forecast 2018-2028
- 5.5.2.1 Rocephin
- 5.5.2.2 Rocephin: Sales Forecast 2018-2028
- 5.5.3. F. Hoffmann-La Roche AG: SWOT Analysis
- 5.6 Sanofi: Overview
- 5.6.1. Sanofi: Antibiotics Drugs Portfolio
- 5.6.2 Sanofi Antibiotics Drug Sales Forecast 2018-2028
- 5.6.2.1 Targocid
- 5.6.2.2 Targocid: Sales Forecast 2018-2028
- 5.6.2.3 Others
- 5.6.2.4 Others: Sales Forecast 2018-2028
- 5.6.3 Sanofi: SWOT Analysis
- 5.7 STADA Arzneimittel: Overview
- 5.7.1. STADA Arzneimittel: Antibiotics Drugs Portfolio
- 5.7.2 STADA Arzneimittel Antibiotics Drug Sales Forecast 2018-2028
- 5.7.2.1 Amoxicillin
- 5.7.2.2 Amoxicillin: Sales Forecast 2018-2028
- 5.7.2.3 Diclofenac Sodium
- 5.7.2.4 Diclofenac Sodium: Sales Forecast 2018-2028
- 5.7.3 STADA Arzneimittel: SWOT Analysis
- 6. Leading Japan Antibiotics Drugs Manufacturers 2018-2028
- 6.1 Shionogi & Co., Ltd.: Overview
- 6.2.1 Shionogi & Co., Ltd.: Antibiotics Drugs Portfolio
- 6.1.2 Shionogi & Co., Ltd. Antibiotics Drug Sales Forecast 2018-2028
- 6.1.2.1 Flomox/Flumarin
- 6.1.2.2 Flomox/Flumarin: Sales Forecast 2018-2028
- 6.1.2.3 Others
- 6.1.2.4 Others: Sales Forecast 2018-2028
- 6.1.3 Shionogi & Co., Ltd.: SWOT Analysis
- 6.2 Taisho Pharmaceutical Holdings: Overview
- 6.2.1 Taisho Pharmaceutical Holdings: Antibiotics Drugs Portfolio
- 6.2.2 Taisho Pharmaceutical Holdings Antibiotics Drug Sales Forecast 2018-2028
- 6.2.2.1 Geninax
- 6.2.2.2 Geninax: Sales Forecast 2018-2028
- 6.2.2.3 Biaxin/Clarith
- 6.2.2.4 Biaxin/Clarith: Sales Forecast 2018-2028
- 6.2.2.5 Zosyn/Tazocin
- 6.2.2.6 Zosyn/Tazocin: Sales Forecast 2018-2028
- 6.2.2.7 Other
- 6.2.2.8 Other: Sales Forecast 2018-2028
- 6.2.3. Taisho Pharmaceutical Holdings: SWOT Analysis
- 6.3 Daiichi Sankyo: Overview
- 6.3.1 Daiichi Sankyo: Antibiotics Drugs Portfolio
- 6.3.2 Daiichi Sankyo Antibiotics Drug Sales Forecast 2018-2028
- 6.3.2.1 Cravit
- 6.3.2.2 Cravit: Sales Forecast 2018-2028
- 6.3.2.3 Levaquin
- 6.3.2.4 Levaquin: Sales Forecast 2018-2028
- 6.3.2.5 Others
- 6.3.2.6 Others: Sales Forecast 2018-2028
- 6.3.3. Taisho Pharmaceutical Holdings: SWOT Analysis
- 6.4 Meiji Holdings Company, Ltd.: Overview
- 6.4.1. Meiji Holdings Company, Ltd.: Antibiotics Drugs Portfolio
- 6.4.2 Meiji Holdings Company, Ltd. Antibiotics Drug Sales Forecast 2018-2028
- 6.4.2.1 Meiact/Spectracef
- 6.4.2.2 Meiact/Spectracef: Sales Forecast 2018-2028
- 6.4.2.3 Others
- 6.4.2.4 Others: Sales Forecast 2018-2028
- 6.4.3. Meiji Holdings Company, Ltd
- 6.5 Astellas Pharma: Overview
- 6.5.1 Astellas Pharma: Antibiotics Drugs Portfolio
- 6.5.2 Astellas Pharma Antibiotics Drug Sales Forecast 2018-2028
- 6.5.2.1 Dificid
- 6.5.2.2 Dificid: Sales Forecast 2018-2028
- 6.5.2.3 Others
- 6.5.2.4 Others: Sales Forecast 2018-2028
- 6.5.3. Astellas Pharma
- 7. Leading Others Antibiotics Drugs Manufacturers 2018-2028
- 7.1 Sun Pharmaceutical Industries: Overview
- 7.1.1 Sun Pharmaceutical Industries: Antibiotics Drugs Portfolio
- 7.1.2 Sun Pharmaceutical Industries Antibiotics Drug Sales Forecast 2018-2028
- 7.1.2.1 Ciprofloxacin Hydrochloride
- 7.1.2.2 Ciprofloxacin Hydrochloride: Sales Forecast 2018-2028
- 7.1.2.3 Others
- 7.1.2.4 Others: Sales Forecast 2018-2028
- 7.1.3 Sun Pharmaceutical Industries: SWOT Analysis
- 7.2 Cipla: Overview
- 7.2.1 Cipla: Antibiotics Drugs Portfolio
- 7.2.2 Cipla Antibiotics Drug Sales Forecast 2018-2028
- 7.2.2.1 Amoxicillin
- 7.2.2.2 Amoxicillin: Sales Forecast 2018-2028
- 7.2.2.3 Others
- 7.2.2.4 Others: Sales Forecast 2018-2028
- 7.2.3. Cipla
- 7.3 Lupin Limited: Overview
- 7.3.1 Lupin: Antibiotics Drugs Portfolio
- 7.3.2 Lupin Antibiotics Drug Sales Forecast 2018-2028
- 7.3.2.1 Cefixime
- 7.3.2.2 Cefixime: Sales Forecast 2018-2028
- 7.3.2.3 Cephalexin
- 7.3.2.4 Cephalexin: Sales Forecast 2018-2028
- 7.3.2.5 Others
- 7.3.2.6 Others: Sales Forecast 2018-2028
- 7.3.3. Lupin: SWOT Analysis
- 7.4 Shanghai Pharmaceuticals Holding: Overview
- 7.4.1. Shanghai Pharmaceuticals Holding: Antibiotics Drugs Portfolio
- 7.4.2 Shanghai Pharmaceuticals Holding Antibiotics Drug Sales Forecast 2018-2028
- 7.4.2.1 Cefotaxime Sodium
- 7.4.2.2 Cefotaxime Sodium: Sales Forecast 2018-2028
- 7.4.2.3 Cefotiam Hydrochloride
- 7.4.2.4 Cefotiam Hydrochloride: Sales Forecast 2018-2028
- 7.4.2.5 Ceftriaxone Sodium
- 7.4.2.6 Ceftriaxone Sodium: Sales Forecast 2018-2028
- 7.4.3. Shanghai Pharmaceuticals Holding: SWOT Analysis
- 7.5 Dr. Reddy’s Laboratories: Overview
- 7.5.1 Dr. Reddy’s Laboratories: Antibiotics Drugs Portfolio
- 7.5.2.1 Amoxil
- 7.5.2.2 Amoxil: Sales Forecast 2018-2028
- 7.5.2.3 Ciprofloxacin Hydrochloride
- 7.5.2.4 Ciprofloxacin Hydrochloride: Sales Forecast 2018-2028
- 7.5.3. Dr. Reddy’s Laboratories: SWOT Analysis
- 7.6 TaiGen Biotechnology: Overview
- 7.6.1. TaiGen Biotechnology: Antibiotics Drugs Portfolio
- 7.6.2 TaiGen Biotechnology Antibiotics Drug Sales Forecast 2018-2028
- 7.6.2.1 Taigexyn
- 7.6.2.2 Taigexyn: Sales Forecast 2018-2028
- 7.4.3. TaiGen Biotechnology
- 8. Conclusions
- 8.1 The World Antibiotics Drugs Market in 2016 and 2017
- 8.1.1 Current Leading Antibiotics Drugs Segments
- 8.1.2 Leading Antibiotics Drugs Manufacturer Markets
- 8.2 World Antibiotics drugs Market Forecast 2018-2028
- 8.3 The Future of the Antibiotics drugs Market?
- Appendix
- Associated Visiongain Reports
- Visiongain Report Sales Order Form
- About Visiongain
- Visiongain Report Evaluation Form
- List of Tables
- Table 3.1 Global Antibiotics Drugs Market by Product Type: Revenue ($m) and Market Share (%), 2017
- Table 3.2 Global Antibiotics Drugs Market Forecast, By Automation Type: Revenues ($m), AGR (%), CAGR (%), 2016-2028
- Table 3.3 Top 10 Antibiotics Drugs Manufacturer: Revenue ($m), Market Share (%), 2017
- Table 3.4 Top 25 Antibiotics Drugs Manufacturer Revenue ($m), 2017
- Table 3.5 Global Antibiotics Drugs Market Forecast, By Manufacturer: Revenues ($m), AGR (%), CAGR (%), 2016-2028
- Table 3.6 Global Antibiotics Drugs Market Forecast, By Product Type: Revenues ($m), AGR (%), CAGR (%), 2016-2028
- Table 3.7 Cephalosporins Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
- Table 3.8 Penicillins Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
- Table 3.9 Fluoroquinolones Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
- Table 3.10 Macrolides Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
- Table 3.11 Carbapenems Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
- Table 3.12 Others Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
- Table 4.1 Pfizer, Inc.: Overview, 2018
- Table 4.2 Pfizer: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
- Table 4.3 Pfizer Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.4 Pfizer: Sulperazon Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.5 Pfizer: Unasyn Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.6 Pfizer: Zithromax Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.7 Pfizer: Dalacin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.8 Pfizer: Merrem/Meropen Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.9 Pfizer: Zyvox Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.10 Pfizer: Tygacil Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.11 Pfizer: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.12 Pfizer: Antibiotics Drugs Market SWOT Analysis, 2018-2028
- Table 4.13 Merck & Co.: Overview, 2018
- Table 4.14 Merck & Co.: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
- Table 4.15 Merck & Co. Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.16 Merck & Co.: Cubicin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.17 Merck & Co.: Invanz Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.18 Merck & Co.: Avelox Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.19 Merck & Co.: Primaxin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.20 Merck & Co.: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.21 Merck & Co.: Antibiotics Drugs Market SWOT Analysis, 2018-2028
- Table 4.22 Johnson & Johnson: Overview, 2018
- Table 4.23 Johnson & Johnson: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
- Table 4.24 Johnson & Johnson Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.25 Johnson & Johnson: Zeftera Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.26 Johnson & Johnson: Sirturo Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.27 Johnson & Johnson: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.28 Johnson & Johnson: Antibiotics Drugs Market SWOT Analysis, 2018-2028
- Table 4.29 Cubist Pharmaceuticals: Overview, 2018
- Table 4.30 Cubist Pharmaceuticals: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
- Table 4.31 Cubist Pharmaceuticals Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.32 Cubist Pharmaceuticals: Cubicin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.33 Cubist Pharmaceuticals: Sivextro Oral Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.34 Cubist Pharmaceuticals: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.35 Cubist Pharmaceuticals: Antibiotics Drugs Market SWOT Analysis, 2018-2028
- Table 4.36 Abbott Laboratories: Overview, 2018
- Table 4.37 Abbott Laboratories: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
- Table 4.38 Abbott Laboratories Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.39 Abbott Laboratories: Baxin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.40 Abbott Laboratories: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.41 Abbott Laboratories: Antibiotics Drugs Market SWOT Analysis, 2018-2028
- Table 4.42 Eli Lilly & Co.: Overview, 2018
- Table 4.43 Eli Lilly & Co.: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
- Table 4.44 Eli Lilly & Co. Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.45 Eli Lilly & Co.: Vancocin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
- Table 4.46 Eli Lilly & Co.: Ceclor Revenue ($m), AGR (%) and CAGR (%), 2016-2021
- Table 4.47 Eli Lilly & Co.: Antibiotics Drugs Market SWOT Analysis, 2018-2028
- Table 4.48 Melinta Therapeutics, Inc.: Overview, 2018
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBookOther tasks
